Space Peptides, a Space Pharmaceuticals company, will invest approximately USD 150 million to build state-of-the-art manufacturing facilities, expanding to an annual capacity of 1100 kg to support scaling of peptide active pharmaceutical ingredient production to clinical and commercial manufacturing, covering therapeutic areas of women’s health, metabolic diseases, antimicrobial and onco-immunology.
The new facility will have an area of approximately 80,000 square meter, with the latest manufacturing technology. Construction of the manufacturing facility is expected to finish in Dec 2022, whereas the plant is expected to be fully operational in 2023.
“The investment is supported by a strong market demand, strong pipeline and underlines Space Peptides’ continuing commitment to serving the peptide pharmaceutical market across scales”, says Dr. Runze He, CEO of Space Pharmaceuticals.